← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
CVA21 (Coxsackievirus A21, Coxsackievirus A21 (CVA21))
Viralytics·Malignant Melanoma
15 trials
Overview
Program
Coxsackievirus A21 (CVA21)
Overview
Company
Viralytics
Overview
Modality
CGT
Overview
Target
Malignant Melanoma
Overview
Indication
Malignant Melanoma
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b…
Clinical
Safety signal
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b…
Clinical
Selected reported efficacy
ORR 39.3%
Clinical
Reported ORR
39.3%
Clinical
Result source
ClinicalTrials.gov NCT04152863
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT04152863